BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1854 related articles for article (PubMed ID: 22461641)

  • 21. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
    Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
    PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
    Rodić N; Anders RA; Eshleman JR; Lin MT; Xu H; Kim JH; Beierl K; Chen S; Luber BS; Wang H; Topalian SL; Pardoll DM; Taube JM
    Cancer Immunol Res; 2015 Feb; 3(2):110-5. PubMed ID: 25370533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.
    Chapon M; Randriamampita C; Maubec E; Badoual C; Fouquet S; Wang SF; Marinho E; Farhi D; Garcette M; Jacobelli S; Rouquette A; Carlotti A; Girod A; Prévost-Blondel A; Trautmann A; Avril MF; Bercovici N
    J Invest Dermatol; 2011 Jun; 131(6):1300-7. PubMed ID: 21346771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
    World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PRAME Expression in Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
    Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
    Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.
    Ghebeh H; Mohammed S; Al-Omair A; Qattan A; Lehe C; Al-Qudaihi G; Elkum N; Alshabanah M; Bin Amer S; Tulbah A; Ajarim D; Al-Tweigeri T; Dermime S
    Neoplasia; 2006 Mar; 8(3):190-8. PubMed ID: 16611412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.
    Nakanishi J; Wada Y; Matsumoto K; Azuma M; Kikuchi K; Ueda S
    Cancer Immunol Immunother; 2007 Aug; 56(8):1173-82. PubMed ID: 17186290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
    Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
    Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
    Franz L; Alessandrini L; Fasanaro E; Gaudioso P; Carli A; Nicolai P; Marioni G
    Ann Diagn Pathol; 2021 Feb; 50():151657. PubMed ID: 33189034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
    Wang S; Liechty B; Patel S; Weber JS; Hollmann TJ; Snuderl M; Karajannis MA
    J Neurooncol; 2018 May; 138(1):183-190. PubMed ID: 29427150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
    Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ROCK1 and ROCK2 Are Down-regulated in Aggressive and Advanced Skin Melanomas - A Clinicopathological Perspective.
    Kaczorowski M; Biecek P; Donizy P; Pieniążek M; Matkowski R; Hałoń A
    Anticancer Res; 2020 Apr; 40(4):1931-1942. PubMed ID: 32234882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
    Pelekanou V; Barlow WE; Nahleh ZA; Wasserman B; Lo YC; von Wahlde MK; Hayes D; Hortobagyi GN; Gralow J; Tripathy D; Porter P; Szekely B; Hatzis C; Rimm DL; Pusztai L
    Mol Cancer Ther; 2018 Jun; 17(6):1324-1331. PubMed ID: 29588392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response.
    Quandt D; Fiedler E; Boettcher D; Marsch WCh; Seliger B
    Clin Cancer Res; 2011 May; 17(10):3100-11. PubMed ID: 21378130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.
    Liu J; Hamrouni A; Wolowiec D; Coiteux V; Kuliczkowski K; Hetuin D; Saudemont A; Quesnel B
    Blood; 2007 Jul; 110(1):296-304. PubMed ID: 17363736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 93.